脱敏治疗的耐久性机械循环支持患者心脏移植后三年结局
该研究纳入2010至2016年连续689例心脏移植受者,分为脱敏机械循环支持组(A组,n=21)、脱敏非机械循环支持组(B组,n=28)和未脱敏组(C组,n=640),比较移植后3年结局。A组与C组在原发性移植物功能障碍、3年生存率、心脏移植物血管病变免除率、非致命主要不良心脏事件、任何治疗性排斥、急性细胞排斥和抗体介导排斥方面相当。
要点
- A组脱敏前群体反应性抗体高于B组(92.2±9.8 vs 83.3±15.6,P=0.007),脱敏后降幅更大(-22.2±26.9 vs -6.3±7.5,P=0.015)。
- A组与C组在原发性移植物功能障碍、3年生存率、心脏移植物血管病变免除率、非致命主要不良心脏事件、任何治疗性排斥、急性细胞排斥和抗体介导排斥方面相当。
- A组3年抗体介导排斥免除率在数值上高于B组,但未达统计学显著;A组与B组感染并发症相似。
核心结论
- 对机械循环支持患者进行脱敏治疗显示群体反应性抗体显著降低,从而扩大了供体池;脱敏机械循环支持患者移植后结局与同期未脱敏对照患者相当,提示脱敏治疗的安全性和有效性。
研究设计与样本
- 研究为2010至2016年连续纳入689例心脏移植受者的队列分析,分为A组(脱敏机械循环支持患者,n=21)、B组(脱敏非机械循环支持患者,n=28)和C组(所有未脱敏患者,n=640)。
主要发现
- A组与B组的脱敏治疗方案相似,包括利妥昔单抗/静脉注射免疫球蛋白和血浆置换/硼替佐米的组合。
- A组脱敏前群体反应性抗体为92.2±9.8,B组为83.3±15.6(P=0.007);A组脱敏后群体反应性抗体降幅为-22.2±26.9,B组为-6.3±7.5(P=0.015)。
- A组与C组在原发性移植物功能障碍、3年生存率、心脏移植物血管病变免除率、非致命主要不良心脏事件、任何治疗性排斥、急性细胞排斥和抗体介导排斥方面相当。
- A组3年抗体介导排斥免除率在数值上高于B组,但未达统计学显著;A组与B组感染并发症相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risks and benefits of desensitization therapy (DST) in highly sensitized mechanical circulatory support (MCS) patients are not well known. We investigated 3 year post-transplant outcomes of desensitized durable MCS patients. METHODS: Among 689 consecutively enrolled heart transplantation recipients between 2010 and 2016, we categorized them into Group A (desensitized MCS patients, n = 21), Group B (desensitized non-MCS patients, n = 28) and Group C (all nondesensitized patients, n = 640). Post-transplant outcomes included the incidence of primary graft dysfunction, 3-year survival, freedom from cardiac allograft vasculopathy, nonfatal major adverse cardiac events, any treated rejection, acute cellular rejection, antibody mediated rejection (AMR) and infectious complications. RESULTS: The types of DST in Groups A and B were similar and included combinations of rituximab/intravenous immunoglobulin and plasmapheresis/bortezomib. Group A, compared with Group B, showed significantly higher pre-DST panel reactive antibody (PRA) (92.2 ± 9.8 vs. 83.3 ± 15.6, P = 0.007) and higher PRA reduction after DST (-22.2 ± 26.9 vs. -6.3 ± 7.5, P = 0.015). Groups A and C showed comparable primary graft dysfunction, 3-year survival, freedom from cardiac allograft vasculopathy, nonfatal major adverse cardiac events, any treated rejection, acute cellular rejection, and AMR. Although statistically not significant, Group A showed numerically higher 3-year freedom from AMR than Group B. Infectious complications were similar in both Groups A and B. CONCLUSIONS: DST for MCS patients showed significant PRA reduction, resulting in an expansion of the donor pool. The post-transplant outcome of desensitized MCS patients showed comparable clinical outcomes to non-desensitized control patients in the same study period, revealing the safety and efficacy of DST.
引用
- Youn JC, Kim D, Jung MH, et al. Three year post heart transplant outcomes of desensitized durable mechanical circulatory support patients. J Heart Lung Transplant. 2023. PMID: 37150473. doi:10.1016/j.healun.2023.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。